Elpis Biopharmaceuticals
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
128 Spring St, Lexington, Massachusetts,...Phone Number
(781) 691-3580Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a clinical-stage biopharma company focused on developing next-generation cell therapies for solid tumors. The company offers a pipeline of innovative bispecific armored CAR-T therapies aimed at addressing tumor heterogeneity and the immunosuppressive tumor microenvironment. Their proprietary technologies include multi-mechanism armor technology and a rapid mRNA display discovery engine, which enhance therapeutic efficacy and safety. Elpis's lead programs target glioblastoma and a variety of solid tumors, catering to patients in need of advanced cancer treatments.Explore more
Elpis Biopharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elpis Biopharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Elpis Biopharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Elpis Biopharmaceuticals
Elpis Biopharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Elpis Biopharmaceuticals launches new products
Funding: Get notified immidiatlly once Elpis Biopharmaceuticals has new funding data
Check if Elpis Biopharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Elpis Biopharmaceuticals is spiking on competitors!
Click to see if Elpis Biopharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Elpis Biopharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Elpis Biopharmaceuticals
Compare insights from companies similar to Elpis Biopharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Elpis Biopharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Elpis Biopharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Elpis Biopharmaceuticals.
Elpis Biopharmaceuticals financials insights
Gather financial insights about Elpis Biopharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Series A
$30M
2021
Debt
$251K
Elpis Biopharmaceuticals Tech Stack
A closer look at the technologies used by Elpis Biopharmaceuticals
See more technologies
Most Recent Scoops
Partnership
Project
Partnership, Research & Development, Business Development, Medical Research, Pharmaceuticals, Clinical Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Funding
Elpis Biopharmaceuticals has received an SBA PPP loan in the amount of $251,777 from JPMorgan Chase resulting in the retention of 22 jobs.
Funding
Funding
Elpis Biopharmaceuticals News & Media
Elpis Biopharmaceuticals and Singapore General Hospital Enter Research Collaboration Agreement to Develop Next Generation Allogeneic CAR Technologies
Agreement focuses on advancing armored and bi-specific CAR-γδTs for AML and multiple myeloma LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today...Elpis Biopharmaceuticals to Present New Data on Multi-Mechanism Armored CAR-T Therapy at PEGS Summit 2025
Proprietary cytokine-engineered CAR-T therapy shows durable anti-tumor activity and low-dose efficacy in solid tumors LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies...Elpis Biopharmaceuticals to Present Two "Late-Breaking" Posters Detailing Its Pioneering CAR-T Cell Therapy Technologies at AACR Annual Meeting 2025
Research highlights potential of EPC-002 in the treatment of solid tumors and EPC-003 for the treatment of glioblastoma LEXINGTON, Mass. and SINGAPORE, April 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T...Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Elpis Biopharmaceuticals today presented two posters at the American Association for Cancer Research (AACR) Annual Meeting.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elpis Biopharmaceuticals
Sign Up For FreeTo access detailed company insights
Elpis Biopharmaceuticals is a clinical-stage biopharma company focused on developing next-generation cell therapies for solid tumors. The company offers a pipeline of innovative bispecific armored CAR-T therapies aimed at addressing tumor heterogeneity and the immunosuppressive tumor microenvironment. Their proprietary technologies include multi-me... Read More
